Larimar Secures PRIME Designation In EU For Neurological Disease Drug
Support Scheme Accepts Potential Treatment For Friedreich’s Ataxia
Executive Summary
The European Medicines Agency has accepted Larimar’s potential treatment for Friedreich’s ataxia onto its PRIME scheme for helping to get medicines for unmet medical needs to patients faster.